Literature DB >> 23685020

Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.

Jatinder Goyal1, Gregory R Pond2, Matthew D Galsky3, Ryan Hendricks3, Alexander Small3, Che-Kai Tsao3, Guru Sonpavde4.   

Abstract

OBJECTIVES: The independent prognostic effect of comorbidities on outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) is unclear. We sought to determine whether the Charlson comorbidity index (CCI) and hypertension (HTN) are associated with overall survival (OS) independent of known clinical prognostic factors in mCRPC. PATIENTS AND METHODS: A retrospective analysis was conducted on 221 patients with mCRPC treated with docetaxel plus prednisone combined with AT-101 (bcl-2 antagonist) or placebo on a prospective randomized phase II trial. The Cox regression analysis was performed to identify whether the CCI or HTN or both (by medical history) independently predicted OS after adjusting for baseline variables known to be associated with OS. The Wilcoxon rank sum test and the Fisher exact test were used to compare data by comorbidity groups (CCI as a continuous variable, CCI = 6 vs. CCI ≥ 7 and HTN vs. no HTN).
RESULTS: The CCI was 6 in 116 patients (52.7%), 7 in 70 (31.8%), 8 in 23 (10.5%), 9 in 4 (1.8%), and 10 in 7 patients (3.2%). HTN was present in 107 (48.6%) patients. Patients with CCI of ≥ 7 were older and exhibited worse performance status and anemia than patients with CCI of 6 (P<0.05). The CCI was not independently predictive of OS on univariable and multivariable analyses. HTN alone or in combination with the CCI was borderline significantly associated with OS (P ~ 0.09) on both univariable and multivariable analyses.
CONCLUSIONS: The CCI did not predict OS independent of known prognostic factors in mCRPC. Age, performance status, and anemia may adequately capture comorbidities in the context of mCRPC, given their association with higher CCI. Further prospective study of comorbidities in a larger data set may be warranted. The study of HTN in a larger data set may also be warranted given its borderline-independent association with OS.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Charlson comorbidity index; Docetaxel; Hypertension; Metastatic castration-resistant prostate cancer; Overall survival; Progression-free survival

Mesh:

Substances:

Year:  2013        PMID: 23685020     DOI: 10.1016/j.urolonc.2013.02.015

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  4 in total

1.  Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide.

Authors:  Yi-Ting Lin; Yen-Chun Huang; Chih-Kuan Liu; Tian-Shyug Lee; Mingchih Chen; Yu-Ning Chien
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

2.  Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel.

Authors:  Andrej Zist; Eitan Amir; Alberto F Ocana; Bostjan Seruga
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

3.  Impact of Comorbidities on Survival in Gastric, Colorectal, and Lung Cancer Patients.

Authors:  Toshitaka Morishima; Yoshifumi Matsumoto; Nobuyuki Koeda; Hiroko Shimada; Tsutomu Maruhama; Daisaku Matsuki; Kayo Nakata; Yuri Ito; Takahiro Tabuchi; Isao Miyashiro
Journal:  J Epidemiol       Date:  2018-07-14       Impact factor: 3.211

4.  A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.

Authors:  Giuseppe Fallara; Rolf Gedeborg; Anna Bill-Axelson; Hans Garmo; Pär Stattin
Journal:  PLoS One       Date:  2021-07-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.